Ocular Therapeutix (OCUL) & The Competition Financial Survey

Ocular Therapeutix (NASDAQ:OCUL) is one of 896 public companies in the “Pharmaceuticals” industry, but how does it compare to its competitors? We will compare Ocular Therapeutix to related companies based on the strength of its institutional ownership, profitability, dividends, valuation, analyst recommendations, earnings and risk.

Institutional & Insider Ownership

59.2% of Ocular Therapeutix shares are owned by institutional investors. Comparatively, 32.5% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 3.1% of Ocular Therapeutix shares are owned by insiders. Comparatively, 14.2% of shares of all “Pharmaceuticals” companies are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Earnings and Valuation

This table compares Ocular Therapeutix and its competitors revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Ocular Therapeutix	$51.95 million	-$265.94 million	-4.64
Ocular Therapeutix Competitors	$3.54 billion	$3.17 billion	554.50

Ocular Therapeutix’s competitors have higher revenue and earnings than Ocular Therapeutix. Ocular Therapeutix is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Analyst Recommendations

This is a summary of recent ratings and price targets for Ocular Therapeutix and its competitors, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ocular Therapeutix	1	1	8	1	2.82
Ocular Therapeutix Competitors	7792	13886	25777	1037	2.41

Ocular Therapeutix currently has a consensus target price of $23.33, indicating a potential upside of 254.07%. As a group, “Pharmaceuticals” companies have a potential upside of 25.59%. Given Ocular Therapeutix’s stronger consensus rating and higher possible upside, research analysts plainly believe Ocular Therapeutix is more favorable than its competitors.

Profitability

This table compares Ocular Therapeutix and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Ocular Therapeutix	-579.10%	-59.89%	-45.99%
Ocular Therapeutix Competitors	-2,372.59%	-220.82%	-15.99%

Risk and Volatility

Ocular Therapeutix has a beta of 1.22, meaning that its stock price is 22% more volatile than the S&P 500. Comparatively, Ocular Therapeutix’s competitors have a beta of -3.62, meaning that their average stock price is 462% less volatile than the S&P 500.

Summary

Ocular Therapeutix beats its competitors on 8 of the 13 factors compared.

About Ocular Therapeutix

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company’s sustained-release hydrogel in combination with Regeneron’s large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.